Roche and Actavis Agree on Product Transactions
Divestment of three Roche pharmaceutical products to Actavis underlines strong focus on key therapy areasBASEL, Switzerland, Aug. 13, 2007-Roche and Actavis, a leading generic pharmaceutical company based in Iceland, have signed agreements for the sale of three Roche pharmaceutical products to Actavis. All product rights - with some territorial exceptions - for Bezalip and Rapilysin, both used in the cardiovascular field, and for the dermatology product Neotigason are being transferred to Actavis. In Latin America Roche will continue to distribute the products under a license of Actavis. In 2006 these three products had combined sales of 140 million Swiss francs. The transactions are expected to close in stages in late 2007 and early 2008, subject to standard closing conditions. The financial terms are not disclosed.
These transactions further underline Roche's strategy of focusing on core products from its innovation-driven pharmaceutical and diagnostic divisions, two businesses with significant potential for high value creation, both for the patients and the company.
About Roche
Headquartered in Basel, Switzerland, Roche is one of the world's
leading research-focused healthcare groups in the fields of
pharmaceuticals and diagnostics. As the world's biggest biotech
company and an innovator of products and services for the early
detection, prevention, diagnosis and treatment of diseases, the
Group contributes on a broad range of fronts to improving people's
health and quality of life. Roche is the world leader in in-vitro
diagnostics and drugs for cancer and transplantation, a market
leader in virology and active in other major therapeutic areas such
as autoimmune diseases, inflammation, metabolic disorders and
diseases of the central nervous system. In 2006 sales by the
Pharmaceuticals Division totalled 33.3 billion Swiss francs, and
the Diagnostics Division posted sales of 8.7 billion Swiss francs.
Roche has R&D agreements and strategic alliances with numerous
partners, including majority ownership interests in Genentech and
Chugai, and invests approximately 7 billion Swiss francs a year in
R&D. Worldwide, the Group employs about 75,000 people.
Additional information is available on the Internet at www.roche.com.
All trademarks used or mentioned in this release are protected by law.
Additional information - Actavis: www.actavis.com
Roche Group Media Office Phone: +41 -61 688 8888 / e-mail: basel.mediaoffice@roche.com - Daniel Piller (Head of Roche Group Media Office) - Baschi Dürr - Martina Rupp - Claudia Schmitt
F. Hoffmann-La Roche Ltd Corporate Communications Grenzacherstrasse 124 4070 Basel, Switzerland
Phone: +41 61 68 88888 Fax: +41 61 68 82775 mailto:basel.mediaoffice@roche.com www.roche.com
Pharma Industry News Archive
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec
